A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early t-precursor acute lymphoblastic leukemia/lymphoma patient

Basit Öğe Kaydı
dc.contributor.authorYiğit Kaya, Süreyya
dc.contributor.authorVatani, Mehrad
dc.contributor.authorAkil, Rima
dc.contributor.authorÇakır, Tansel
dc.contributor.authorMaral, Senem
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorSevindik, Ömür Gökmen
dc.date.accessioned2026-04-16T07:01:52Z
dc.date.available2026-04-16T07:01:52Z
dc.date.issued2025
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.description.abstractEarly T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone. This regimen achieved complete remission after one cycle. This case highlights the potential of this combination therapy as an effective treatment for refractory ETP-ALL/LBL, suggesting further research is warranted to validate its efficacy and safety.
dc.identifier.citationYiğit Kaya, S., Vatani, M., Akil, R., Çakır, T., Maral, S., Kaynar, L. ... Sevindik, Ö. G. (2025). A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early t-precursor acute lymphoblastic leukemia/lymphoma patient. Annals of Hematology, 104(1), 829-833. http://dx.doi.org/10.1007/s00277-024-06118-8
dc.identifier.doi10.1007/s00277-024-06118-8
dc.identifier.endpage833
dc.identifier.issn0939-5555
dc.identifier.issn1432-0584
dc.identifier.issue1
dc.identifier.pmid39847114
dc.identifier.scopus2-s2.0-85217269991
dc.identifier.scopusqualityQ2
dc.identifier.startpage829
dc.identifier.urihttp://dx.doi.org/10.1007/s00277-024-06118-8
dc.identifier.urihttps://hdl.handle.net/20.500.12511/13430
dc.identifier.volume104
dc.identifier.wosWOS:001403269800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYiğit Kaya, Süreyya
dc.institutionauthorVatani, Mehrad
dc.institutionauthorAkil, Rima
dc.institutionauthorÇakır, Tansel
dc.institutionauthorMaral, Senem
dc.institutionauthorKaynar, Leylagül
dc.institutionauthorid0009-0001-5191-174X
dc.institutionauthorid0009-0008-0309-4109
dc.institutionauthorid0000-0002-7685-2766
dc.institutionauthorid0000-0003-4766-1861
dc.institutionauthorid0000-0002-2035-9462
dc.language.isoen
dc.relation.ispartofAnnals of Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAllogeneic Hemopoietic Stem Cell Transplantation
dc.subjectAzacitidine
dc.subjectDaratumumab
dc.subjectVenetoclax
dc.subjectDexamethasone
dc.subjectEarly T-Precursor Acute Lymphoblastic Leukemia/Lymphoma
dc.titleA complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early t-precursor acute lymphoblastic leukemia/lymphoma patient
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Yiğit Kaya-Süreyya-2025.pdf
Boyut:
706.49 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu